Marshall Fordyce Sells 23,125 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 23,125 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total value of $1,064,906.25. Following the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at $14,182,110.60. The sale was disclosed in a filing with the SEC, which is available through this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, September 11th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50.
• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $43.44 on Monday. Vera Therapeutics, Inc. has a 1-year low of $9.24 and a 1-year high of $50.78. The company’s 50-day moving average is $38.40 and its 200 day moving average is $39.03. The firm has a market capitalization of $2.38 billion, a P/E ratio of -21.19 and a beta of 0.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Research analysts forecast that Vera Therapeutics, Inc. will post -2.57 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. upped their price objective on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $51.75.

Institutional Trading of Vera Therapeutics

A number of large investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new stake in Vera Therapeutics during the 1st quarter valued at about $227,027,000. Kynam Capital Management LP raised its stake in Vera Therapeutics by 23.5% in the fourth quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock worth $56,142,000 after buying an additional 694,286 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Vera Therapeutics during the 1st quarter valued at $103,189,000. Vanguard Group Inc. boosted its position in Vera Therapeutics by 31.5% during the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after acquiring an additional 515,106 shares in the last quarter. Finally, Samlyn Capital LLC increased its holdings in shares of Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.